Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 158 Jul 28 – Oct 25, 2026
- Disclosed funding
- $6B 122 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| UI United ImmunityCompany profile A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. | ¥2.2B | Private financingUndisclosed | Biotech | Japan | Investors Aozora HYBRID Fund IIIFujita TT Impact Fund I +11ITOCHU CorporationJoyo Bank, Ltd.Kobe University Fund IMitsubishi UFJ Life Sciences Fund IIMiyako Kyoto University Innovation Fund IIIMizuho Life Sciences Fund INVCC Fund 10Ono Venture Investment, Inc.Ricoh Biomedical Startup Investment Limited PartnershipSaisei Bioventures L.P.UTEC Fund V Limited Partnership | |
| BB BigHat BiosciencesCompany profile An AI and synthetic-biology platform that designs and engineers antibody therapeutics. An AI and synthetic-biology platform that designs and engineers antibody therapeutics. | $75M | Series CSeries C+ | Biotech | United States | Investors | |
| E EnginZymeCompany profile EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. | SEK 75M | Equity roundUndisclosed | Biotech | Sweden | Investors | |
| TT Tempo TherapeuticsCompany profile A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. | ≤$2.3M | NCI SBIR grantUndisclosed | Biotech | United States | Investors | |
| BR Basecamp ResearchCompany profile Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines. Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines. | $140M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| E EnvedaCompany profile Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases. Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases. | $311M | Series ESeries C+ | Biotech | United States | Investors | |
| AL Azulene LabsCompany profile Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research. Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research. | $3.4M | Pre-SeedPre-seed | Biotech | — | Investors | |
| PB Primrose BioCompany profile Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines. Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines. | Undisclosed | Growth financingGrowth | Biotech | United States | Investors | |
| C CellsBinCompany profile A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring. A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring. | Undisclosed | Series A | Biotech | United States | Investors | |
| MT Molecular Targeting Technologies, Inc.Company profile A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis. A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis. | $3.2M | National Cancer Institute R01 grantUndisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 28, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.